Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab

NCT07013123 is registered in ClinicalTrials.gov with University Hospital, Montpellier as lead sponsor.

NCT NCT07013123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07013123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab
Lead sponsor
University Hospital, Montpellier
Phase
Phase 3
Overall status
Not yet recruiting
Start date
July 15, 2025
Completion date
August 18, 2029
Enrollment
38 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

allergy to house dust mites, severe asthma